tag:blogger.com,1999:blog-6278250556678332358Fri, 01 Nov 2024 11:30:22 +0000Food and Drug AdministrationClinical trialBiotechnology and PharmaceuticalsFDAGlaxoSmithKlineArena PharmaceuticalscancerHuman Genome SciencesJazz PharmaceuticalsWikInvestEli LillyNovartisVivusJazzMerckTheStreetAlkermesAmgenBristol-Myers SquibbBusinessInvestingNew Drug ApplicationPfizerPharmaceuticalsRocheARNAAnti-obesity medicationDendreonGSKALXAAlexza PharmaceuticalsBenlystaBiogen IdecBiotechForest LaboratoriesHGSISanofi-AventisTop Performing Biotech Pharmaceuticals StocksWarren BuffettAVNRAstraZenecaBiotechnologyClinical TrialsDaiichi SankyoFDA approvalLorcaserinMarketWatchNVSQnexaSVASeattle GeneticsSwine influenzaSystemic lupus erythematosusAVI BioPharmaAmylinAmylin PharmaceuticalsAntibioticBMYBSDMBiodelColorectal cancerELNFDA Advisory PanelFRXGenzymeGlaxo SmithKlineInfluenzaJohnson and JohnsonLung cancerLupusMedical DeviceMonoclonal antibodiesNew York Stock ExchangePhentermine/topiramatePrescription Drug User Fee ActSanofi AventisSchering-PloughSeeking AlphaStocks and BondsU.S. Food and Drug AdministrationchemotherapyAbbott LaboratoriesAcadia PharmaceuticalsAstellas PharmaBSD MedicalBiovailBreast cancerCHTPDEPOElan CorporationEndo PharmaceuticalsEuropean Society for Medical OncologyExact SciencesFDA CalendarFDA RecommendationGenentechGeronGoogleH1N1Health careInfectious diseaseInsulinKing PharmaceuticalsMRKMethicillin-resistant Staphylococcus aureusNon-Hodgkin's LymphomaNon-small cell lung carcinomaNovavaxOncologyOrexigen TherapeuticsOrexigen Therapeutics Inc.PharmaceuticalPharmaceutical industryProstate cancerQCORQuestcor PharmaceuticalsSinovac BiotechSpectrum PharmaceuticalsStockTeva Pharmaceutical IndustriesThomson ReutersType 2 DiabetesVRXVVUSWSJWall Street JournalZymoGeneticsbiopharmastock quote2010 Drug ApprovalsABTACADARQLARYXAZ-004Alzheimer's TreatmentAntibioticsArQuleArenaAriad PharmaceuticalAvanirAvian influenzaBCRXBVFBank of AmericaBayer AGBerkshire HathawayBioPharmaceuticalsBiopharmaceuticalBoehringer IngelheimBreaking NewsCLDACPIXCYTKCancer ResearchCeftarolineCelgeneCervical cancerChelsea TherapeuticsChronic myelogenous leukemiaColonoscopy ExamContraveCraig VenterCumberland PharmaceuticalsCurisDDSSDIJADNADNDNDiagnostic ScreeningDow Jones Industrial AverageEXASEli Lilly and CompanyExact scienceFDA Special Protocol AssessmentFV-100Facet BiotechFederal Reserve SystemFlu seasonFree DonationsGERNGamma-Hydroxybutyric acidGardasilGoutHIVHLCSHealthHemispherx BioPharmaHepatitis C virusHoffmann–La RocheHuman Genome ProjectHuman papillomavirusILMNINHXIdenixInhibitexJ. Craig Venter InstituteJZP-6Jim CramerJimmy VLupus Foundation of AmericaMNKDMRSAMSRAMultiple SclerosisNASDAQNasdaq CompositeNew England Journal of MedicineNovo NordiskObesity DrugPGPPHMPeregrine PharmaceuticalsPhase 3Proctor and GambleProvengeRHHBFRHHBYRPCResearch and DevelopmentSGENSLXPSOMXSPEXSVNTSavient PharmaceuticalsSequenomShinglesSolvay PharmaceuticalsSomaxonSubstance dependenceSucampoSwine FluTRBNTakeda PharmaceuticalTakeda Pharmaceutical CompanyTalecrisTalecris BiotherapeuticsTop Biotech StocksTop Performing BioPharma StocksTranscept PharmaceuticalsTrastuzumabTysabriValeant PharmaceuticalValeant PharmaceuticalsVivitrolWall StreetWashington PostXyremZGENcancer therapycancer treatmentnanotechnology$ATRS000 now10 Rules of Investing BioPharma1971987 Stock Crash2011 Biotech Preview3Q Earnings3Q Preview483 Letter510K60 MinutesACURADA meetingADCAIDSAIDSVAXALIMTAALKSALXNAMGNAMLAQ197ARIAARYx TherapeuticsASTMAVIIAZ-004 FDA RecommendationAZNAastrom BiosciencesAbraxis BioScienceAcetaminophenActharActhar GelActiPatch deviceAcute myeloid leukemiaAdam FeuersteinAddictionsAdsense AdsAerocrineAfrezzaAlcohol AddictionAlexionAlfred MannAlgetaAllayAllerganAllos TherapeuticsAlzheimerAlzheimer's diseaseAmerican Association for Cancer ResearchAmerican Cancer SocietyAmerican Diabetes AssociationAmerican Stock ExchangeAmyotrophic lateral sclerosisAnacor PharmaceuticalsAnaplastic lymphoma kinaseAnit-bioticsAntaresAnti-JC Virus AssayAntibiotic resistanceAntibody-Drug ConjugatesAntidepressantAntiretroviral drugAntiviralApple IncArtificial gene synthesisAvanir STAR Clinical TrialBDXBIIBBIODBIOSBLTIBRAFBRKRBSD Medical CorporationBSDM FDA 510K Clearance MDX-180 BSD MedicalBSPMBankrupt NationBarack ObamaBavituximabBaxterBayerBeckman CoulterBecton DickinsonBeijing Genomics InstituteBelimumabBerkeley Software DistributionBernard MadoffBernie Madoff PropertyBernie Madoff YachtBest Biotechnology BlogBevacizumabBig PharmaBio run up principleBioCenturyBioCrystBioCryst PharmaceuticalsBioDelivery SciencesBioElectronics CorporationBioMarinBioPharma BlogBioPharma InvestmentsBioPharma Stock UpdatesBioPharma Top PerformersBioRunUpBiogenBiolaseBiologic License ApplicationBiologicsBiopharma InvestingBiorunup.comBiotech 2011Biotech BlogBiotech IPOBiotech StocksBiotechnology IndexBiotechnology StocksBiovaxIDBiovestBlack MondayBlood ThinnerBlood cancerBlood pressureBond BubbleBond ETFsBone metastasisBoston ScientificBrain CancerBrain tumorBrentuximabBrentuximab vedotinBristolBristol MyersBristol Myers ZymoGenetics MergerBristol-MeyersBristol-MyersBroad InstituteBuffalo NewsCBRXCBSCDCCELGCPHICRLCROCTICCVMCYCCCYPBCancer DetectionCancer Diagnostic ScreeningCancer Diagnostic TestCancer Diagnostic TestingCancer DrugsCancer ScreeningCancer TreatmentsCancer VaccineCannabis ScienceCapriprazineCardiomyocytesCardium TherapeuticsCel-Sci Corp.Celera GenomicsCell TherapeuticsCellartisCellectisCellular DynamicsCepheidCerezymeCervarixCharles PonziChicken Pox VirusChinaChina AnalystChina Pharma HoldingsChinese BiopharmaceuticalsChinese BiotechCiproCitigroupClass Action LawsuitClass actionClick on the Ads PleaseClinical DataClinical Trial FailureClostridium difficileCloud ComputingCoca-ColaColon CancerComplicated skin and skin structure infectionCompugenComputerized Drug DiscoveryCorporate BondsCorporate bondCotaraCredit Card RantCredit cardCritical Limb IschemiaCrizotinibCrohn's diseaseCubicinCubist PharmaceuticalsCubist PharmaceuticsCyclacelCypress BiosciencesCystic FibrosisCystinosisCytRxCytokineticsDDDDNA sequencingDNEXDUSADVAXDainippon Sumitomo PharmaDan FussDana–Farber Cancer InstituteDebtor's RevoltDenosumabDentistryDepomedDepressionDiabetes MedicationDiabetes mellitusDiabetes mellitus type 1Diagnostic TestingDiamyd MedicalDonationsDopey CowboysDown syndromeDr. VenterDrexel Burnham LambertDroxidopaDrug DiscoveryDynPortDynPort VaccineEMSOEXACEXELEarningsEarnings Preview 3QEat Pray LoveEconomic Stimulus TARP MarketwatchEfavirenzEisaiEmbryonic stem cellEmergent BioSolutionsEmerging MarketsEmtricitabineEpilepsy DrugEquity Top PicksErythromycinEscherichia coliEscherichia coli O157:H7EvaluatePharma 2014 forecastExchange-traded fundFDA CRLFDA DecisionFDA DecisionsFDA DelaysFDA Drug Approvals ContestFDA NewsFDA PanelFDA ReviewFDA rejectionFacebookFailureFast CrashFibromyalgiaFinancial servicesFloxapenFlu ShotFood Drug AdministrationForeign BondsForest LabsFundraiserFundraisingFuture Biotech InnovationsGENGENZGalvusGamunexGenerexGenerex BiotechGenericGeneric DrugsGenericsGenetic Engineering and Biotechnology NewsGenetic disorderGeneticsGenlenyaGenome StudyGermanyGeron CorporationGilead SciencesGirard BibbsGlioblastoma multiformeGlobeNewswireGoogle Apple ChickGoogle FinanceGoogle GirlGordon GekkoGreat DepressionH1N1 StocksHCVHEBHITKHIV vaccineHPVHPV Oral CancerHPV cancerHPV vaccineHRA PharmaHSICHarry BoxerHead and neck cancerHealth Care Billion Dollar Bill Drugmakers BioPharma MedicareHeat Treatment for CancerHelicosHelicos BioSciencesHenry ScheinHerpes ZosterHi-Tech PharmacalHigh Risk Heart FailureHindenburg OmenHodgkin lymphomaHopsiraHospiraHoward Hughes Medical InstituteHuluHuman GenomeHuman Genome ScienceHyperthermia Cancer TreatmentHypotensionIBSICGNILIIMGNINX-189IRSBISCOISTA PharmaceuticalsImmunoGenIncretin PathwayInduced Pluripotent Stem CellsInfantile SpasmsInfectionInfertilityInfluenza A virus subtype H1N1Influenza A virus subtype H5N1Influenza pandemicInfluenza researchInhalable insulinInsomniaInstitute of Cancer ResearchInsulin TherapyInterferon beta-1bIntermezzoIpilimumabIrritable bowel syndromeJ. Craig VenterJAZZ. PRANJC virusJCV-Antibody AssayJNJJP Morgan Healthcare ConferenceJanuary CatalystsJanuviaJapanese StocksJazz PharmaceuticalJennifer AnistonJeremy SiegelJimmy FallonJimmy V LogoJimmy ValvanoJohns HopkinsJohnson N JohnsonJulie RobertsKGKV.AKey DevelopmentsKodroff and WillisKrystexxaLIFELLYLaserLate Stage CancerLawfirmsLawsuitsLegacy of HopeLegacy of Hope SocietyLeukemiaLife TechnologiesLinjetaLymphomaMBCIMDEAMELA SciencesMILMSMTDMYLMabCureMad MoneyMadoff's Property Up For AuctionMagnetic resonance imagingMajor depressive disorderManagement of cancerMannKind CorporationMarcadia BiotechMark ZuckerbergMarket Snapshot Dow JonesMasters Degree OnlineMax BaucusMcAfeeMcClellan OscillatorMedImmuneMedarexMedical Device StocksMedical EquipmentMedicareMelaFindMelanomaMens CancerMergers and AcquisitionsMichael DouglasMichael MilkenMicroRNAMike Havrilla Seeking Alpha BioMedReportsMikeHavRx.comMillennium OncologyMillennium PharmaceuticalsMilliporeMoney (magazine)Money MagazineMoney Never SleepsMonoclonal antibodyMoodyMoody'sMorgantownMovie TrailerMultiple Myeloma Research FoundationMutual Pharmaceutical CompanyMylan PharmaceuticalMyriad GeneticsNCNDM-1NSCLCNVAXNaltrexoneNanodrugsNarcolepsyNational Institute of Allergy and Infectious DiseasesNational Institute on AgingNew DelhiNew Delhi metallo-beta-lactamaseNewsmakers in the Biotech Industry ConferenceNick Burns the Computer GuyNon-Hodgkin's lymphoma SPPI Spectrum PharmaceuticalsNon-small cell lung cancerNon-steroidal anti-inflammatory drugNorth CarolinaNovaceaNutra PharmaONXXOPXAOREXOSI PharmaceuticalsOXGNObesityObesity DrugsOliver StoneOlivia Newton-JohnOlympia SnoweOne Team One CauseOnglyzaOnko-SureOnline Masters Degree ProgramsOnline advertisingOnxyOpioid AddictionOpioid DependenceOptimer PharmaceuticalsOutbreakOvarian cancerPBT2PDL BioPharmaPDLIPFEPKIPMLPPCOPRXLPain TherapiesPain managementPancreatic cancerParkinson's Disease PychosisParkinsons DiseasePatent Expiring 2011Patent ProtectionPelpinPerkinElmerPfizer (PFE) and India's Ranbaxy Laboratories (RBXLF)Pfizer. LipitorPharmaceutical BlogPharmaceutical drugPhase IIPhase II Clinical TrialPhase IIIPhase III Clinical TrialsPictures Of Bernie Madoff's Yacht'sPimavanserinPimcoPittsburgh Post-GazettePlavixPonzi schemePotential Market MoversPotigaPradaxaPrana BiotechnologyPrecious Metal DerivativesPrenatal TestingPresident ClintonPrimary immunodeficiencyProfit marginProgressive multifocal leukoencephalopathyPromotionProstate-specific antigenProtalixProtalix BiotherapeuticsProtein-bound paclitaxelPseudobulbar affectPsoriasisPublic HealthPurdue PharmaceuticalsQ4 Drug ApprovalsQGENQuintiles White PapersRIGLRNA-dependent RNA polymeraseRPTPRXIIRadient PharmaceuticalRaient PharmaceuticalsRaptor PharmaceuticalsRare diseaseRegenerative MedicineReproCellResearch Triangle ParkRestless Leg SyndromeReturn on equityReutersRevenueReverse transcriptase inhibitorRevolution MedicalRexahnRheumatoid arthritisRigel PharmaceuticalsRituxanRobert Koch InstituteRoche HoldingRodman RenshawRosemanRussell 3000(R) and Russell 2000(R) Indexes SPPISKBISNYSPPISQNMSUNHSafety IVSafety Syringe RevVacSalix PharmaceuticalsSavient PharmaceuticalSciCloneSearch engineSepracorShireSilenorSkystar BiopharmSmartMoneySomaxon PharmaceuticalsSpectorSpectrum Pharmaceuticals Added to the Russell Global(R)Spells Doom 52-week highsSpherixSt Jude MedicalStaccato SystemStaph AureusStaph InfectionStatinStem CellsStem Cells InternationalStem cellStem cells. Embryonic stem cellSteve JobsSteve KroftStock CrashStock DeclineStock RallyStock marketStock market crashStocks for the Long RunSubstance abuseSuperbugsSwine Flu HumorSwine Flu OutbreakSwine Flu StocksSymptomatic Neurogenic Orthostatic HypotensionSynthetic BiologySythetic GenomicTKPHFTLCRTMOTSPTTags: BIIBTalecris IPOTenofovirThe Medicines CompanyThe Next Wave of Medical MoneymakersThe SnowballThe StreeThe V FoundationTheravanceTodd GolubTop Biotechnology BlogTop Biotechnology StocksTop Drug DevelopmentTop Japanese BiopharmaTop Metabolic DrugsTop Rated Stocks: BiotechnologyTransceptTranscription (genetics)TriusTroubled Asset Relief ProgramTrubion PharmaceuticalsTruvadaTylenolUnited States CongressUric acidVZVVaccineVaccine ProductionValtrexVaricella Zoster VirusVaxGenVeralookVertex PharmaceuticalsVictozaVilazodoneViroproVirtual colonoscopyVirulent Skin GermsWATWVWall Street 2Wall Street Stock CrashWall Street: Money Never SleepsWall Street: Money Never SleepsWarning Bear MarketWarren Buffett's Berkshire HathawayWeb Design and DevelopmentWeblogsWeekend at Bernie'sWeight lossWhat Percentage Are Your Investments in One Stock?What is MSRA?What to do with 10When Will The Recovery StartWhy It's Time To Be BullishWilliam PrattWyethX-ray computed tomographyXGEVAXOMADXomaYahooYahoo FinanceYoutube Videoalliantares pharmaantares pharmaceuticalsantares stockantares stock quoteapprovalatrsatrs stock quotebest tradesbiopharma investorcatalystschelseaclinicalcnbccodingdue diligenceePROellagaucher diseasegood buyiCADiSteminfraredinvestmentinvestmentsinvestorlannettlcimedicinemeg terrillmelanoma drugmuscular dystrophynanoparticlenanoshellnew 52-week lowsobamaobamacareprGCDprogrammingrafaximinsantarussareptasarepta therapeuticsscmpsearchsntssrptstock buystock investmentsstockstax revolttop pickstop stocktrialstwittertype 1 diabetesBioPharma Investments ranging from Biotech, Pharmaceutical, & Medical Devices. Stocks in the Healthcare Sector. Top Stock Performers in a High Risk/High Reward Market. BioPharma Run-up Principles Based on Clinical Trial Recommendations by the FDA. Mergers and Acquisitions coverage. News from The Street and Jim Cramer MadMoney Picks. Stocks Based on Science not Hype. http://biopharmainvestor.blogspot.com/noreply@blogger.com (Unknown)Blogger209125tag:blogger.com,1999:blog-6278250556678332358.post-6650931871551589363Thu, 07 Jul 2016 01:23:00 +00002016-07-07T21:44:49.393-04:00approvalBiotechcatalystsClinical trialcnbcFDAmeg terrillmuscular dystrophyPharmaceuticalssareptasarepta therapeuticssrptStockstock quoteWith the recent FDA delay, what's the deal with Sarepta Therapeutics.  Seems like a sure thing but then why would the FDA delay their decision and request more data. A good look at their clinical trail is in the WSJ this week.  Where's the drug FDA? The Food and Drug Administration is sitting on a therapy for Duchenne muscular dystrophy, and the agency may have days to waste but thehttp://biopharmainvestor.blogspot.com/2016/07/sarepta-therapeutics-fda-delay.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-59877486019895492Thu, 27 Aug 2015 22:45:00 +00002016-07-06T20:12:32.444-04:00Bio run up principlebiopharmaBiotechClinical trialcodinginvestmentsPharmaceuticalprogrammingStockstock investmentsstock quote So it's been a minute.  The principles of the Bio Pharmaceuticals of Stock investments still runs true today. I plan on continuing with the Biopharma process and provide more Data Analytical approach with Financial Data in Biotech and Pharmaceuticals.  I went back to school for computer programming and data analysis and now work for a healthcare company in finance. Can't wait to http://biopharmainvestor.blogspot.com/2015/08/biopharma-investor-further-development.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-4662632144159972071Fri, 26 Jul 2013 21:40:00 +00002013-07-26T17:43:25.089-04:00best tradesbiopharmaBiotechchelseaCHTPlannettlciobamaobamacarePharmaceuticalsantarusscmpsntsstock quotestocksSucampotop pickstop stockBelow are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader.  It's all free.  I would never ask you to pay for anything on my site.  No catches, no gimmicks. If you want to search for other Sectors or other Countries, you can check them out here: 4-Trader.com Stock Sector http://biopharmainvestor.blogspot.com/2013/07/4-best-biopharma-stock-trades-2013.htmlnoreply@blogger.com (Unknown)tag:blogger.com,1999:blog-6278250556678332358.post-4337733269079503529Fri, 07 Jun 2013 18:18:00 +00002016-07-17T11:16:07.918-04:00$ATRSAntaresantares pharmaantares pharmaceuticalsantares stockantares stock quoteatrsatrs stock quotebiopharmadue diligencegood buyinvestmentinvestorSeeking Alphastock buytwitter Antares Pharmaceuticals is a Hot Biopharma Investment Right Now   So let's start off with Antares Pharma. Most of my previous stocks that I have written about have done very well in the past few years so I'll continue with that trend with this stock: ATRS. ATRS FDA Approval PDUFA Date is Oct. 14th      Antares Pharma Here's a few web links to help you out on Antares http://biopharmainvestor.blogspot.com/2013/06/antares-pharma-atrs-risky-buy-that.htmlnoreply@blogger.com (Unknown)tag:blogger.com,1999:blog-6278250556678332358.post-5118799205306611128Mon, 16 Apr 2012 11:10:00 +00002013-05-21T19:25:35.560-04:00biopharma investorWe are working on creating a new full feature design for BioPharma Investor here soon.  Hopefully a better website and more updated content.  Thanks for your patience while I get this up and running.  Web Design and Database Programming doesn't happen overnight. http://biopharmainvestor.blogspot.com/2012/04/future-of-biopharma-investor.htmlnoreply@blogger.com (Unknown)tag:blogger.com,1999:blog-6278250556678332358.post-8865256971354943494Sat, 09 Jul 2011 01:13:00 +00002011-07-08T21:15:39.151-04:0060 MinutesArtificial gene synthesisCBSCelera GenomicsCraig VenterDNAHuman Genome ProjectJ. Craig Venter InstituteSteve KroftSynthetic BiologyImage via WikipediaJ. Craig Venter: Designing Life June 12, 2011 5:00 PM Steve Kroft profiles famous microbiologist J. Craig Venter, whose scientists have already mapped the human genome and created what he calls "the first synthetic species." Read more: http://www.cbsnews.com/video/watch/?id=7369820n&tag=cbsnewsMainColumnArea.8#ixzz1RZ052a3e (CBS News)  This story was first http://biopharmainvestor.blogspot.com/2011/07/60-minutes-on-j-craig-venter-designing_08.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-1687301607045268797Thu, 30 Jun 2011 13:13:00 +00002011-06-30T09:13:17.423-04:00AmgenAriad PharmaceuticalBristol-MeyerscancerCancer TreatmentschemotherapyClinical TrialsCurisLate Stage CancerOnxyPfizerRocheImage via WikipediaFrom FierceBiotech For the cancer drug research enthusiast, this report might read in places like a special oncology edition of a gun magazine. Indeed, there are plenty of weapons against cancer to read about here. Several of the drugs listed here represent the advancement of relatively new methods of attacking cancer, including "armed antibodies" and cancer-killing http://biopharmainvestor.blogspot.com/2011/06/cancer-clinical-trials-and-treatments.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-3487101377810117197Tue, 28 Jun 2011 10:34:00 +00002011-06-28T06:34:43.361-04:00Beijing Genomics InstituteEscherichia coliEscherichia coli O157:H7GermanyLife TechnologiesRobert Koch InstituteImage via WikipediaAs of June 15, the number of people who were ill due to the outbreak of a new E. coli strain in Europe had reached 3,244, according to the Associated Press (AP). Most of the reports have been in Germany, and 784 of the total had developed a serious complication that could lead to kidney failure. AP reported that 37 people have died in Germany, and one person died in Swedenhttp://biopharmainvestor.blogspot.com/2011/06/killer-e-coli-strain-identified-in.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-438877753141630600Tue, 28 Jun 2011 10:22:00 +00002011-06-28T06:22:50.000-04:00Anacor PharmaceuticalsClinical TrialsPsoriasisImage via Wikipedia Anacor Pharmaceuticals (NASDAQ:ANAC) announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis. The trial enrolled 68 subjects randomized in a 2:1 ratio, AN2728 to vehicle. Subjects treated with AN2728 showed improvement over vehicle at each of the recorded timepoints http://biopharmainvestor.blogspot.com/2011/06/anacor-pharmaceuticals-and-psoriasis.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-3665980476377409925Tue, 28 Jun 2011 10:09:00 +00002011-06-28T06:10:41.354-04:00AmgenBiologic License ApplicationBone metastasisDenosumabFood and Drug AdministrationGlaxoSmithKlineOlivia Newton-JohnProstate cancerXGEVAImage via WikipediaTHOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approvedhttp://biopharmainvestor.blogspot.com/2011/06/amgen-submits-bla-for-xgeva.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-2649603836994854318Tue, 28 Jun 2011 10:04:00 +00002011-06-28T06:04:28.695-04:00Anaplastic lymphoma kinasecancerClinical trialCrizotinibFood and Drug AdministrationLung cancerNon-small cell lung carcinomaPfizerImage via CrunchBase Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 (PF-299) an investigational, oral, pan-HER inhibitor;1 and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,2 at the International Association for the Study of Lung http://biopharmainvestor.blogspot.com/2011/06/pfizers-to-present-lung-cancer-data.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-6299789461760734205Tue, 28 Jun 2011 09:50:00 +00002011-06-28T06:15:02.450-04:00ADA meetingAstraZenecaBoehringer IngelheimBristol-Myers SquibbDiabetes mellitus type 1Eli LillyInsulinNovo Nordisktype 1 diabetesType 2 DiabetesImage via WikipediaGEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA Meeting The American Diabetes Association (ADA) meeting in San Diego included the presentation of new data from Phase III trials evaluating Bristol-Myers Squibb (BMS) and AstraZeneca’s dapagliflozin, Boehringer Ingelheim and Eli Lilly’s linagliptin, and Novo Nordisk’s http://biopharmainvestor.blogspot.com/2011/06/gen-news-highlightsfirms-report.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-1670255955973210067Tue, 28 Jun 2011 09:47:00 +00002011-06-28T05:49:29.815-04:00Clinical TrialsCloud ComputingCROePROJohns HopkinsPublic HealthGEN | Analysis & Insight: Cloud Computing Augments Clinical Trial Process (Page 1 of 1)Pharma and biotech companies have so far tended to use cloud computing services for drug development research, not clinical trials. IBM and other smaller tech companies would like to change all that, though. Additionally, applying cloud computing for data analysis to aid http://biopharmainvestor.blogspot.com/2011/06/gen-analysis-insight-cloud-computing.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-703553308263513971Thu, 02 Jun 2011 09:28:00 +00002011-06-02T06:22:20.101-04:00Cervical cancerGardasilHead and neck cancerHPVHPV cancerHPV Oral CancerHuman papillomavirusMens CancerMerckMRKThroat Cancer Linked to HPV By LAURA LANDRO A sharp rise in a type of throat cancer among men is increasingly being linked to HPV, the sexually transmitted human papillomavirus that can cause cervical cancer in women. A new study from the National Cancer Institute warns that if recent trends continue, the number of HPV-positive oral cancers among men could rise by nearly 30% by 2020. At thathttp://biopharmainvestor.blogspot.com/2011/06/recent-news-concerning-hpv-in-men-hpv.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-3773103493845998214Sun, 27 Mar 2011 03:18:00 +00002011-03-26T23:18:57.374-04:00BristolBristol-Myers SquibbcancerClinical trialFood and Drug AdministrationIpilimumabMelanomamelanoma drugThomson Reuters By Bill BerkrotNEW YORK | Mon Mar 21, 2011 6:37pm EDT (Reuters) - Bristol-Myers Squibb Co's eagerly anticipated experimental drug ipilimumab extended survival of previously untreated patients with advanced melanoma in a late stage study, the company said. Details of how much longer patients who were suffering from the deadly skin cancer lived after taking the http://biopharmainvestor.blogspot.com/2011/03/bristol-melanoma-drug-extends-survival.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-7698094583486322115Sun, 27 Mar 2011 02:39:00 +00002011-03-26T23:07:50.740-04:00Blood cancerBRAFBroad InstituteCancer ResearchDaiichi SankyoDana–Farber Cancer InstituteGenome StudyHoward Hughes Medical InstituteMultiple Myeloma Research FoundationTodd Golub Bio Technician demonstrates the loading of the high tech 454 Life Science sequencing machine in the sequencing laboratory at the J. Craig Venter Institute in Rockville, Maryland, in this March 29, 2010 file photo. Credit: Reuters/Larry Downing (UNITED STATES - Tags: SCI TECH) Image via Wikipedia(Reuters) -  By Julie SteenhuysenCHICAGO | Wed Mar 23, 2011 2:17pm EDT  http://biopharmainvestor.blogspot.com/2011/03/genome-study-brings-blood-cancer-into.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-142767099830871024Mon, 31 Jan 2011 02:09:00 +00002011-01-30T21:10:19.741-05:00Craig VenterDNADNA sequencingDr. VenterGeneticsHuman Genome ProjectJ. Craig VenterJ. Craig Venter InstitutePerkinElmerPKITranscription (genetics)Image via Wikipedia Perkins Elmer has an extensive history in the genomic sequencing field and Dr. Craig Venter. Dr. Venter is a former researcher for The Institute for Genomic Research and founded the J. Craig Venter Institute.  Find out more  here:  http://www.jcvi.org/ Google finance:  NYSE:PKI PerkinElmer Website PerkinElmer Enters DNA Sequencing Market By MATTHEW http://biopharmainvestor.blogspot.com/2011/01/perkinselmer-genomic-sequencing-history.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-6933102997665664040Fri, 28 Jan 2011 03:05:00 +00002011-01-27T22:05:17.896-05:00AntidepressantBiotechnology StocksCLDAClinical DataMajor depressive disorderTop Biotech StocksTop Rated Stocks: BiotechnologyVilazodoneImage via Wikipedia Top Rated Stocks: BiotechnologyTop Rated Stocks 01/27/11 Clinical Data Website Clinical Data Pipeline Clinical Data--Google Finance  CLDA January 24, 2011Clinical Data, Inc. Announces FDA Approval of Viibryd™ (vilazodone HCl) for Major Depressive DisorderRSS Feed for Top Rated Stocks: Biotechnology Every day TheStreet Ratings produces a list of the top rated stocks.http://biopharmainvestor.blogspot.com/2011/01/top-rated-biotechnolgy-stocks-street.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-7407467632640696781Thu, 27 Jan 2011 22:17:00 +00002011-01-27T21:27:21.488-05:00ALXNAMGNBMYCLDAILMNLLYMNKDMRKNVSOPXAPDLIPFESVNTTags: BIIBTop BioHealth Research Calls of the Week (MNKD, PDLI, ILMN, CLDA, MRK, PFE, LLY, BMY, ALXN, SVNT, AMGN) January 22, 2011 · Filed Under Financial, analyst calls, fda · Comment  There were some key research calls in biotech and biohealth shares this week.  Over in our “top five analyst calls of the week” at 24/7 Wall Street we noted how one firm came out in defense of MannKind http://biopharmainvestor.blogspot.com/2011/01/top-biohealth-investor-calls-of-month.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-434115504725088984Fri, 14 Jan 2011 03:34:00 +00002011-01-27T21:14:55.737-05:00AfrezzaAlfred MannClinical trialDiabetes mellitusInhalable insulinInsulinMannKind CorporationMNKDNew Drug ApplicationBiotech and Pharmaceutical news:  Mannkind (MNKD) Google Finance:  MNKD Mannkind Corp.  Website Mannkind Pipeline I am cautious about Mannkind's approval chances with the FDA in the next coming weeks (FDA delayed Dec 29th decision 4 weeks) but I am optimistic about its chances of an increase in stock price while the FDA reviews Mannkind's approval for Afrezza for Diabetes.  http://biopharmainvestor.blogspot.com/2011/01/mannkind-is-having-increased-momentum.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-9063548931279366979Wed, 12 Jan 2011 05:42:00 +00002011-01-12T00:47:16.922-05:00AntiviralBavituximabClinical TrialsHepatitis C virusPancreatic cancerPeregrine PharmaceuticalsPPHM Hepatitis C Virus Image via Wikipedia Peregrine seems poised for growth in 2011 Written by Patrick Crutcher Tuesday, 11 January 2011 Zacks.com Profile:  PPHM Peregrine Pharmaceutical Pipeline Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it has initiated several trials in oncology and viral infections. They seem poised to garner attention from the Street over the cominghttp://biopharmainvestor.blogspot.com/2011/01/another-2011-standout-peregrine.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-1056870641270805235Wed, 12 Jan 2011 02:17:00 +00002011-01-27T21:17:41.012-05:00Biotech 2011Biotech StocksDendreonDepomedEli LillyHuman Genome SciencesJanuary CatalystsSeattle GeneticsSpectrum PharmaceuticalsTop Biotech StocksStocks Mentioned:  Dendreon, Human Genome Sciences, Eli Lilly, Cerus, Curis, Compugen, Spectrum Pharmaceuticals, Impax Laboratories, Exelixis, Medivation, Seattle Genetics, Corcept, PolyMedix, BioMarin, Endo Pharmaceuticals, DepoMed, Mannkind, Orexigen Therapeutics, AstraZeneca, Clinical Data Here are the Top Biotech Picks for 2011, Stocks Highlighted at the JP Morgan Healthcare http://biopharmainvestor.blogspot.com/2011/01/top-biotech-stocks-for-2011-and-january.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-8477326727243078175Tue, 11 Jan 2011 02:49:00 +00002011-01-10T21:52:50.677-05:00Biotechnology and PharmaceuticalsCystinosisRaptor PharmaceuticalsRare diseaseRPTPCysteamine Image via Wikipedia Interest for Raptor Pharmaceuticals is really picking up in 2011.  Here are the recent headlines for this up and coming Small Cap Pharmaceutical company.  It has a Pipeline for Rare Diseases and I expect 2011 to be a strong year for Raptor Pharmaceuticals if Clinical Trial results are successful.  Results for DR Cysteamine clinical trials is http://biopharmainvestor.blogspot.com/2011/01/raptor-pharmaceuticals-in-2011.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-8263461449575314042Sat, 08 Jan 2011 09:01:00 +00002011-01-08T04:01:25.737-05:00chemotherapyClinical trialColorectal cancerFood and Drug AdministrationNew Drug ApplicationRocheSpectrum PharmaceuticalsSPPIViroproSpectrum Pharmaceuticals Submits Supplemental New Drug Application (sNDA) For Ready-to-Use Formulation Of FUSILEV(R) In Colorectal Cancer Main Category: Colorectal Cancer Also Included In: Cancer / Oncology Article Date: 06 Jan 2011 - 1:00 PST Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus http://biopharmainvestor.blogspot.com/2011/01/spectrum-pharmaceuticals-is-making.htmlnoreply@blogger.com (Unknown)0tag:blogger.com,1999:blog-6278250556678332358.post-4170797708099245269Sat, 08 Jan 2011 02:13:00 +00002011-01-07T21:13:06.922-05:002011 Biotech PreviewDendreonJP Morgan Healthcare ConferenceJP Morgan Healthcare Conference 2011 Preview Stocks Mentioned:  AMAG, AMGN, AMLN, ARIA, CELG, DNDN, GENZ, GILD, HGSI, ITMN, KERX, MNKD, NKTR, OREX, SGEN, SNY, SVNT, TEVA, VRTX, VVUS, MRK The Street: Biotech 2011 Kickoff Party Investor Preview By: Adam Feuerstein The biotech industry descends on the City by the Bay starting Sunday for a week of investor meetings, networking, deal making http://biopharmainvestor.blogspot.com/2011/01/2011-biotech-preview-jp-morgan.htmlnoreply@blogger.com (Unknown)0